FOR MORE NEWS HEADLINES AND VIDEOS CLICK HERE
[WISH|VIDEO] Eli Lilly and Co.’s new weight loss drug could be available to patients sooner than expected.
The U.S. Food and Drug Administration granted tirzepatide a fast-track designation, which is a process designed to speed up the review of drugs designed to treat serious medical conditions to patients as soon as possible.
The nation has been struggling with an obesity crisis for decades. Currently, 70% of Americans are considered overweight or obese putting them at risk for heart disease, stroke, Type 2 diabetes.
News 8 reported on Lilly’s phase 3 trial results in June. Researchers assigned over 2,500 overweight and obese adults into 4 groups. Participants were prescribed a weekly injection of either 5, 10, or 15 milligrams of tirzepatide. The fourth group received a placebo. [FULLSTORY]
FOR MORE NEWS HEADLINES AND VIDEOS CLICK HERE
Important Note: This article is for informational purposes only and should not be taken as medical advice. If you are considering using any weight loss drug, it is essential to consult with a licensed healthcare professional first to determine if it is safe and appropriate for you.
Discover more from Your Assignment Editor
Subscribe to get the latest posts sent to your email.
